This proposal is directed at the Phase II development of qualitative and quantitative affinity-based mass spectrometry. Essentially, micro-scale immunoaffinity capture is used to selective isolate and concentrate given proteins from complex mixtures, after which matrix-assisted laser desorption/ionization time-of-flight mass spectrometry is used for sensitive and highly-accurate detection. The approach is further improved by the inclusion of internal standards, e.g., mass-shifted variants of the target proteins, resulting in a viable mass spectrometric immunoassay (MSIA) capable of the rigorous quantitation of proteins present in biological mixtures at sub-nanomolar concentrations.
The specific aims of this proposal are to expand upon our Phase I findings by: 1) Further developing the devices needed for MSIA (MSIA-Tips) by increasing binding capacity and 2) improving surface derivatization methods, 3) Developing a """"""""practice"""""""" MSIA kit for educational purposes, 4) Using MSIA with high-throughput robotics and mass spectrometers, and, 5) Increasing production of MSIA- Tips to meet projected demand at the end of Phase II. Mass spectrometric immunoassay (and associated devices and methods) is viewed as a relatively easy approach for the rapid qualitative and quantitative analysis of proteins, and in the study of protein-protein interactions, and thus stands to have significant impact in health-related research associated with protein characterization.

Proposed Commercial Applications

Potential applications of MSIA include routine screening of expression systems to verify production of recombinant proteins, protein/gene identification of genomic libraries via MS-database search techniques, and the rigorous quantitation of proteins present in natural biological mixtures. The commercial potential of the approach stems from lines of consumables (MSIA-Tips) that can be used singularly in research or in parallel for high- throughput applications and methods/techniques with applications in proteomics or the clinical/diagnostic arena.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44GM056603-02
Application #
6210852
Study Section
Special Emphasis Panel (ZRG1-SSS-6 (01))
Program Officer
Edmonds, Charles G
Project Start
1999-02-01
Project End
2002-08-31
Budget Start
2000-09-01
Budget End
2001-08-31
Support Year
2
Fiscal Year
2000
Total Cost
$260,550
Indirect Cost
Name
Intrinsic Bioprobes, Inc.
Department
Type
DUNS #
965127038
City
Tempe
State
AZ
Country
United States
Zip Code
85284
Kiernan, Urban A; Tubbs, Kemmons A; Nedelkov, Dobrin et al. (2003) Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 537:166-70
Niederkofler, Eric E; Tubbs, Kemmons A; Kiernan, Urban A et al. (2003) Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 44:630-9
Kiernan, Urban A; Tubbs, Kemmons A; Nedelkov, Dobrin et al. (2003) Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2:191-7
Kiernan, Urban A; Tubbs, Kemmons A; Nedelkov, Dobrin et al. (2002) Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem Biophys Res Commun 297:401-5
Kiernan, Urban A; Tubbs, Kemmons A; Gruber, Karl et al. (2002) High-throughput protein characterization using mass spectrometric immunoassay. Anal Biochem 301:49-56
Kiernan, Urban A; Black, Jeff A; Williams, Peter et al. (2002) High-throughput analysis of hemoglobin from neonates using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chem 48:947-9
Niederkofler, E E; Tubbs, K A; Gruber, K et al. (2001) Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 73:3294-9